• Alias: YN968D1; Rivoceranib (international nonproprietary name)
    • Orally bioavailable VEGFR2 (KDR) inhibitor; also mildly inhibits RET, KIT, and SRC
    • FDA-granted orphan drug status for treatment of gastric cancer
    • Recommended phase 3 dose: 850 mg daily
    • Half-life: 9 hours
    • Metabolism: Extensively by CYP3A4
    • Common side effects: Hypertension, hand–foot syndrome, diarrhea, anemia, thrombocytopenia, proteinuria
    (Zhang et al., 2017)
    Other topics in Targeted and Immunotherapy Agents